The company is privately held and is being supported by 8 investors, both private and government. Although mostly Finance investors, they share the excitement inherent to Life Sciences research.
In detail, SIRION Biotech believes in the future of viral vectors in various applications:
- Gene Function Research,
- Target Validation,
- Gene Therapy and
Of those, specifically Gene Therapy & Vaccines attract a great deal of attention with almost $ 1 bn raised over the last 2-3 years. In addition, attractive exits are taking place; recent examples are Okairos and Crucell. The momentum is being accelerated by UniQure’s drug approval by EMA in 11 / 2012.
„Is Gene Therapy Medicine’s Next Big Thing?“, states Todd Campbell of E.B. Capital Markets, LLC on June 14, 2014 on TheMotleyFool, The World’s Greatest Investing Community.Todd is an independent researcher.
„The viral vectors are what will differentiate the various gene therapy approaches“, writes Joshua Schimmer of Piper Jaffray in his study by Lazard Capital Markets titled „Gene Therapy: The Time is Now“.
The company welcomes new investors, be it Finance or Strategic investors, to help it grow even more strongly with the many opportunities along the way and to help it benefit from technology development in this exciting industry, Please contact Management for further information about the company and its future plans.